Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study.
Patients with symptomatic oral lichen planus frequently require therapy to reduce signs and symptoms. For this purpose, corticosteroids are often applied topically. In a randomized, double-blind, placebo-controlled study, the efficacy of the topical application of 0.025% fluocinonide was evaluated. Forty consecutive patients with oral lichen planus diagnosed on the basis of histopathologic and immunofluorescence findings participated in this study. All patients were followed for 3 to 17 months. No adverse effects were noted during follow-up period. In the group of 20 patients that received the drug, 4 patients (20%) showed a complete remission, and 12 patients (60%) had a good or partial response to topical treatment. In the placebo-group, these figures were 0 and 6 (30%), respectively. The majority of the placebo-group (70%) did not respond at all with regard to signs (Xt2 = 10.4; p = 0.0013) and symptoms (Xt2 = 6.97, p = 0.008). The results from this study suggest that topical application of fluocinonide in an adhesive base is a safe and effective drug to reduce signs and symptoms in oral lichen planus.
Voûte
A B
AB
Department of Oral and Maxillofacial Surgery and Oral Pathology, Free University Hospital/Academic Centre for Dentistry, Amsterdam (ACTA), The Netherlands.
Schulten
E A
EA
Langendijk
P N
PN
Kostense
P J
PJ
van der Waal
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005447:Fluocinonide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008010:Lichen Planus / Q000145:classification / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D009823:Ointment Bases; D012074:Remission Induction; D016896:Treatment Outcome
D009823:Ointment Bases; D005447:Fluocinonide